DaVita Inc.

What does DaVita own?
DaVita owns its US and international dialysis clinic network, DaVita Labs, home-dialysis operations, and integrated kidney care business. It does not own hospitals or drug brands.

Is DaVita publicly traded?
Yes. It trades on the NYSE under ticker DVA as an S&P 500 component.

Does Berkshire Hathaway own DaVita?
Berkshire is DaVita's largest shareholder at roughly 40 percent, but does not control it; DaVita remains an independent public company.

What does DaVita mean?
The name comes from the Italian "dare vita," meaning "to give life," adopted in the 2000 rebrand from Total Renal Care.

Who is the CEO of DaVita?
Javier Rodriguez, a longtime company executive, has been CEO since 2019.

How many dialysis centers does DaVita run?
Approximately 2,600 in the United States plus several hundred internationally.

How much revenue does DaVita generate?
Approximately $13 billion annually.

The company's corporate form dates to 1999, when Total Renal Care, a dialysis rollup assembled in the mid-1990s, emerged from financial distress and renamed itself DaVita in 2000, from the Italian phrase "dare vita," to give life.

Under CEO Kent Thiry, who led from 1999 to 2019, DaVita consolidated the fragmented dialysis clinic market into a national platform with a famously strong internal culture, employees are called "teammates," and grew through acquisition to duopoly scale.

The 2010s brought expansion into integrated care: DaVita bought HealthCare Partners for $4.4 billion in 2012, one of the largest medical group acquisitions, later divesting it to UnitedHealth's Optum in 2019.

Berkshire Hathaway began accumulating its stake in 2011 and grew it to a roughly 40 percent position by the 2020s, an unusual concentration even for Berkshire, driven largely by DaVita's own aggressive repurchases shrinking the float.

Rodriguez succeeded Thiry in 2019, steering the company toward home dialysis and value-based kidney care, where CMS's ESRD Treatment Choices model rewards keeping patients out of in-center dialysis.

The company's model sits at the center of healthcare cost debates: dialysis is among Medicare's most expensive per-patient benefits, and DaVita's profit structure depends on commercial-rate premiums that policy critics target.

Labor relations draw scrutiny: the company has faced union-organizing pressure and wage complaints from its predominantly front-line nursing workforce.

Dialysis economics scrutiny: The duopoly structure and commercial-payer premium model attract recurring congressional, academic, and press criticism.

Antitrust settlement: DaVita settled a $34 million federal antitrust case in 2014 over market allocation, part of its regulatory record.

California ballot fights: The company has spent heavily defeating state ballot measures targeting dialysis clinic staffing and profits, among the most expensive industry political campaigns.

Employment litigation: Periodic lawsuits over overtime and scheduling for clinic staff.